Breaking News, Promotions & Moves

Johnson & Johnson Taps New Chief Human Resources Officer

Kristen Mulholland to succeed Dr. Peter M. Fasolo later this year.

Johnson & Johnson has announced that Dr. Peter M. Fasolo will retire from his position as Executive Vice President, Chief Human Resources Officer at the end of this year, following 16 years of leadership and service to the Company.
 
He will be succeeded in this role by Kristen Mulholland, a strong Credo-based leader who has had a notable career across the Company’s Innovative Medicine and MedTech sectors, managed business unit HR for the Company’s global corporate functions, and has led Corporate HR Services including Performance and Development and most recently Global Total Rewards. Mulholland will also be appointed as a member of Johnson & Johnson’s Executive Committee, effective October 1, 2024.
 
Fasolo and Mulholland will work together during a transition period until Dr. Fasolo’s retirement at the end of this year.

About Kristen Mulholland

Mulholland has been with Johnson & Johnson since 2005. She has held HR leadership positions in the Company’s corporate services, global functions and the MedTech and Innovative Medicines sectors across commercial and R&D and helped establish the Company’s Innovation Centers.
 
In her most recent role as Head of Human Resources, Global Total Rewards & Enterprise HR Functions at Johnson & Johnson, she worked closely with the Board of Directors supporting the Compensation & Benefits Committee and played a key role in the separation of the consumer business to form Kenvue.
 
“I’m pleased to appoint Kristen to this important role where she will apply her deep business acumen, talent expertise and Credo-based approach to advance J&J’s culture and operating model,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “I’m confident her breadth of experience and strong leadership will ensure Johnson & Johnson’s human capital strategy is poised to deliver the innovative future-ready talent and culture needed to advance healthcare solutions for patients worldwide.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters